Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Argentine hemorrhagic fever (AHF), caused by the Junin virus (JUNV), is an acute viral hemorrhagic disease characterized by initial fever and malaise followed by gastrointestinal symptoms and in some cases hemorrhagic and neurological manifestations.
No clinical trials have been registered for Argentine hemorrhagic fever.
10 publications have been identified in PubMed for Argentine hemorrhagic fever. Research spans Basic Science / Preclinical (40%), Gene Therapy / Novel Therapeutics (40%), and Review / Meta-Analysis (10%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 4 | 40% |
New treatment approaches | 4 |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 9:15 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Argentine hemorrhagic fever
Research summaries | 1 | 10% |
Disease patterns and progression | 1 | 10% |
Oladipo EK (2026). [PMID: 41930240](https://pubmed.ncbi.nlm.nih.gov/41930240/). *In silico pharmacology*. [Gene Therapy / Novel Therapeutics]
Taylor LJ (2025). [PMID: 40632652](https://pubmed.ncbi.nlm.nih.gov/40632652/). *Cell reports*. [Basic Science / Preclinical]
Ortiz-Prado E (2025). [PMID: 40021105](https://pubmed.ncbi.nlm.nih.gov/40021105/). *Travel medicine and infectious disease*. [Review / Meta-Analysis]
Flores-Pérez N (2025). [PMID: 40576885](https://pubmed.ncbi.nlm.nih.gov/40576885/). *EcoHealth*. [Basic Science / Preclinical]
Urata S (2025). [PMID: 40381661](https://pubmed.ncbi.nlm.nih.gov/40381661/). *Antiviral research*. [Gene Therapy / Novel Therapeutics]
Tomatis C (2025). [PMID: 40514553](https://pubmed.ncbi.nlm.nih.gov/40514553/). *Current microbiology*. [Gene Therapy / Novel Therapeutics]
Thomas PD (2025). [PMID: 39921799](https://pubmed.ncbi.nlm.nih.gov/39921799/). *Genetica*. [Basic Science / Preclinical]
Alissa M (2025). [PMID: 39693032](https://pubmed.ncbi.nlm.nih.gov/39693032/). *Molecular diversity*. [Basic Science / Preclinical]
Westover JB (2024). [PMID: 38945484](https://pubmed.ncbi.nlm.nih.gov/38945484/). *Antiviral research*. [Epidemiology / Natural History]
Nunberg JH (2024). [PMID: 38506509](https://pubmed.ncbi.nlm.nih.gov/38506509/). *Journal of virology*. [Gene Therapy / Novel Therapeutics]
AI-curated news mentioning Argentine hemorrhagic fever
Updated Jul 8, 2026
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.